Citi does not believe that the new case reported in the FDA’s FAERS database of posterior vitreous detachment in a 60-year-old patient is “an unusual occurrence nor likely caused by VIZZ,” leading the firm to recommend buying Lenz Therapeutics (LENZ) amid the “FAERS induced” selloff. The firm, which argues that today’s “overreaction appears unwarranted,” has a Buy rating and $52 price target on Lenz shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Short Report: VNET Group short interest at 4-month high
- Lenz Therapeutics price target lowered to $35 from $52 at BofA
- LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
- Lenz Therapeutics, Sarah Jessica Parker launch ‘Make it VIZZable’
- Robust Early Adoption, Favorable Safety Profile, and Upcoming DTC Campaign Support Buy Rating on VIZZ